126101-07-3Relevant articles and documents
Synthesis and pharmacological activity of a series of dihydro-1H- pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers
Pinza,Farina,Cerri,Pfeiffer,Riccaboni,Banfi,Biagetti,Pozzi,Magnani,Dorigotti
, p. 4214 - 4220 (2007/10/02)
A series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones were synthesized. These bicylic derivatives contain both the 2-pyrrolidinone and 4-imidazolidinone nuclei, already recognized as important for cognition enhancing activity. In addition, these structures maintain the backbone of piracetam and oxiracetam with the acetamide side chain restricted in a folded conformation. Their ability to reverse scopolamine-induced amnesia was assessed in a one trial, step-through, passive avoidance paradigm. The main features observed are a potent antiamnestic activity after ip administration (minimal effective dose being between 0.3 and 1 mg/kg ip for most compounds), the presence of a bell-shaped dose-response curve and, generally, a reduction of biological activity after po administration. However, the unsubstituted compound (15, dimiracetam) shows no evidence of a bell-shaped dose-response curve and completely retains activity when given orally, being 10-30 times more potent than the reference drug oxiracetam.
Psychotropic perhydroazacycloalka [1,2-A] imidazole derivatives
-
, (2008/06/13)
Imidazole derivatives are described which are useful in restoring learning and treating memory difficulties. A compound of the invention is 2,5-dioxohexahydro-1H-pyrrolo[1,2-a]imidazole.
Condensed imidazole derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them.
-
, (2008/06/13)
Compounds of structure (I) in which, R1 is hydrogen, C1 4alkyl, CHR6CONHR7 or CHR6COOR7 in which R6 and R7 are each hydrogen or C1 4alkyl; R2 is hydrogen, C1 5alkyl or a residue R2 of an amino acid R2 CH(NH2)COOH; R3 is hydrogen, C1 4alkyl, CONH2 or CO2R8 in which R8 is hydrogen or C1 4alkyl; and n is 2, 3 or 4, processes for their preparation, intermediates useful in their preparation, pharmaceutical composition containing them and their use in therapy as nootropic agents.